{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:59:28Z","timestamp":1762955968104},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T00:00:00Z","timestamp":1534464000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Impot Res"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1038\/s41443-018-0063-1","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T10:20:30Z","timestamp":1534501230000},"page":"15-19","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie\u2019s disease"],"prefix":"10.1038","volume":"31","author":[{"given":"Peter N.","family":"Tsambarlis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Yong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence A.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,17]]},"reference":[{"key":"63_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","volume":"190","author":"M Gelbard","year":"2013","unstructured":"Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie\u2019s disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199\u2013207.","journal-title":"J Urol"},{"key":"63_CR2","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1016\/j.juro.2012.01.032","volume":"187","author":"M Gelbard","year":"2012","unstructured":"Gelbard M, Lipshultz LI, Tursi J, Smith T, Kaufman G, Levine LA. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol. 2012;187:2268\u201374.","journal-title":"J Urol"},{"key":"63_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0022-5347(17)35998-0","volume":"149","author":"MK Gelbard","year":"1993","unstructured":"Gelbard MK, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie\u2019s disease: a double-blind study. J Urol. 1993;149:56\u20138.","journal-title":"J Urol"},{"key":"63_CR4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/jsm.12731","volume":"12","author":"LA Levine","year":"2015","unstructured":"Levine LA, Cuzin B, Mark S, Gelbard MK, Jones NA, Liu G, et al. Clinical safety and effectiveness of collagenase Clostridium histolyticum injection in patients with Peyronie\u2019s disease: a phase 3 open-label study. J Sex Med. 2015;12:248\u201358.","journal-title":"J Sex Med"},{"key":"63_CR5","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bju.13096","volume":"116","author":"LI Lipshultz","year":"2015","unstructured":"Lipshultz LI, Goldstein I, Seftel AD, Kaufman GJ, Smith TM, Tursi JP, et al. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie\u2019s disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int. 2015;116:650\u20136.","journal-title":"BJU Int"},{"key":"63_CR6","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.juro.2015.10.065","volume":"195","author":"MJ Ziegelmann","year":"2016","unstructured":"Ziegelmann MJ, Viers BR, McAlvany KL, Bailey GC, Savage JB, Trost LW. Restoration of penile function and patient satisfaction with intralesional collagenase clostridium histolyticum injection for Peyronie\u2019s disease. J Urol. 2016;195:1051\u20136.","journal-title":"J Urol"},{"key":"63_CR7","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1590\/s1677-5538.ibju.2016.06.02","volume":"42","author":"RP Terlecki","year":"2016","unstructured":"Terlecki RP, Rasper AM. Data vs dogma in Peyronie\u2019s disease. Int Braz J Urol. 2016;42:1058\u201361.","journal-title":"Int Braz J Urol"},{"key":"63_CR8","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S0022-5347(06)00517-9","volume":"176","author":"WJ Hellstrom","year":"2006","unstructured":"Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie\u2019s disease. J Urol. 2006;176:394\u20138.","journal-title":"J Urol"},{"key":"63_CR9","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/bju.13932","volume":"120","author":"A Abdel Raheem","year":"2017","unstructured":"Abdel Raheem A, Capece M, Kalejaiye O, et al. Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie\u2019s disease using a new modified shortened protocol. BJU Int. 2017;120:717\u201323.","journal-title":"BJU Int"},{"key":"63_CR10","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jsxm.2016.02.105","volume":"13","author":"FA Yafi","year":"2016","unstructured":"Yafi FA, Anaissie J, Zurawin J, Sikka SC, Hellstrom WJ. Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase clostridium histolyticum for Peyronie\u2019s disease. J Sex Med. 2016;13:684\u20139.","journal-title":"J Sex Med"},{"key":"63_CR11","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1111\/jsm.12838","volume":"12","author":"KS Coyne","year":"2015","unstructured":"Coyne KS, Currie BM, Thompson CL, Smith TM. Responsiveness of the Peyronie\u2019s disease questionnaire (PDQ). J Sex Med. 2015;12:1072\u20139.","journal-title":"J Sex Med"},{"key":"63_CR12","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1111\/j.1743-6109.2010.01850.x","volume":"7","author":"D Ralph","year":"2010","unstructured":"Ralph D, Gonzalez-Cadavid N, Mirone V, Perovic S, Sohn M, Usta M, et al. The management of Peyronie\u2019s disease: evidence-based 2010 guidelines. J Sex Med. 2010;7:2359\u201374.","journal-title":"J Sex Med"},{"key":"63_CR13","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1016\/S0022-5347(01)68184-9","volume":"158","author":"LA Levine","year":"1997","unstructured":"Levine LA, Lenting EL. A surgical algorithm for the treatment of Peyronie\u2019s disease. J Urol. 1997;158:2149\u201352.","journal-title":"J Urol"},{"key":"63_CR14","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1111\/jsm.12910","volume":"12","author":"D Papagiannopoulos","year":"2015","unstructured":"Papagiannopoulos D, Yura E, Levine L. Examining postoperative outcomes after employing a surgical algorithm for management of Peyronie\u2019s disease: a single-institution retrospective review. J Sex Med. 2015;12:1474\u201380.","journal-title":"J Sex Med"},{"key":"63_CR15","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.sxmr.2017.12.006","volume":"6","author":"JY Chen","year":"2018","unstructured":"Chen JY, Hockenberry MS, Lipshultz LI. Objective assessments of Peyronie's disease. Sex Med Rev. 2018;6:438\u201345.","journal-title":"Sex Med Rev"},{"key":"63_CR16","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.juro.2013.01.090","volume":"190","author":"WJ Hellstrom","year":"2013","unstructured":"Hellstrom WJ, Feldman R, Rosen RC, Smith T, Kaufman G, Tursi J. Bother and distress associated with Peyronie\u2019s disease: validation of the Peyronie\u2019s disease questionnaire. J Urol. 2013;190:627\u201334.","journal-title":"J Urol"}],"container-title":["International Journal of Impotence Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41443-018-0063-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41443-018-0063-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41443-018-0063-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:27:49Z","timestamp":1684618069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41443-018-0063-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,17]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["63"],"URL":"https:\/\/doi.org\/10.1038\/s41443-018-0063-1","relation":{},"ISSN":["0955-9930","1476-5489"],"issn-type":[{"value":"0955-9930","type":"print"},{"value":"1476-5489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,17]]},"assertion":[{"value":"24 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"LL is a consultant for Boston Scientific, Coloplast Corporation, and Endo Pharmaceuticals. He is a lecturer for Boston Scientific, Coloplast Corporation, and Abbvie Pharmaceuticals. The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}